Literature DB >> 18238747

Hypertensive crisis, catecholamine cardiomyopathy, and death associated with pseudoephedrine use in a patient with pheochromocytoma.

Glen W Sizemore1, Karie E Scrogin, Elliot S Weisenberg, C Michael Weldon-Linne, Omadath B Madoo.   

Abstract

OBJECTIVE: To describe a woman with a previously unrecognized pheochromocytoma who died after ingesting over-the-counter pseudoephedrine-containing medications.
METHODS: We present a case report including laboratory, radiographic, and pathologic findings in a patient with a previously unrecognized pheochromocytoma.
RESULTS: A 31-year-old woman had symptoms consistent with intermittent, excessive release of catecholamines since childhood. She developed an upper-respiratory infection and used over-the-counter medications containing pseudoephedrine. Subsequently, she developed a hypertensive crisis with congestive heart failure and died of a cardiac arrhythmia and shock. Findings from postmortem examination included a right adrenal pheochromocytoma, congestive heart failure, and catecholamine cardiomyopathy.
CONCLUSION: This patient death may be linked to the use of pseudoephedrine hydrochloride. Physicians and pharmacists should warn patients with known pheochromocytoma or those at risk for having pheochromocytoma on the basis of family history or genetic testing that pseudoephedrine use may be harmful. Over-the-counter packaging should include such warning.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18238747     DOI: 10.4158/EP.14.1.93

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  2 in total

1.  Pheochromocytoma presenting as acute decompensated heart failure reversed with medical therapy.

Authors:  Christopher M Mulla; Paul Ellis Marik
Journal:  BMJ Case Rep       Date:  2012-07-19

2.  Attention Deficit Hyperactivity Disorder in Pediatric Patients with Pheochromocytoma and Paraganglioma.

Authors:  M Batsis; U Dagalakis; C A Stratakis; T Prodanov; G Z Papadakis; K Adams; M Lodish; K Pacak
Journal:  Horm Metab Res       Date:  2016-05-12       Impact factor: 2.936

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.